Svoboda | Graniru | BBC Russia | Golosameriki | Facebook

Sexual dimorphism in solid and hematological malignancies

Semin Immunopathol. 2019 Mar;41(2):251-263. doi: 10.1007/s00281-018-0724-7. Epub 2018 Oct 25.

Abstract

Cancer represents a leading cause of death with continuously increasing incidence worldwide. Many solid cancer types in non-reproductive organs are significantly more frequent and deadly in males compared to females. This sex-biased difference is also present in hematologic malignancies. In this review, we present an overview about sex differences in cancer with a focus on leukemia. We discuss mechanisms potentially underlying the observed sex-biased imbalance in cancer incidence and outcome including sex hormones, sex chromosomes, and immune responses. Besides affecting the pathobiology of cancers, sex differences can also influence drug responses, most notably those to immune checkpoint blockers. Therefore, sex should become a relevant factor in clinical trial design in order to avoid over- or under-treatment of one sex.

Keywords: Immune system; Leukemia; Sex difference; Sex hormones.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Chromosomes, Human / genetics
  • Chromosomes, Human / immunology
  • Female
  • Gonadal Steroid Hormones / genetics
  • Gonadal Steroid Hormones / immunology
  • Hematologic Neoplasms / epidemiology
  • Hematologic Neoplasms / genetics
  • Hematologic Neoplasms / immunology*
  • Hematologic Neoplasms / pathology
  • Humans
  • Incidence
  • Leukemia / epidemiology
  • Leukemia / genetics
  • Leukemia / immunology*
  • Leukemia / pathology
  • Male
  • Sex Characteristics*
  • Sex Chromosomes / genetics
  • Sex Chromosomes / immunology

Substances

  • Gonadal Steroid Hormones